Therapeutic role and potential mechanisms of active Vitamin D in renal interstitial fibrosis

被引:56
作者
Tan, Xiaoyue [1 ]
Li, Yingjian [1 ]
Liu, Youhua [1 ]
机构
[1] Univ Pittsburgh, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA
关键词
vitamin D; renal fibrosis; EMT; chronic kidney disease; HGF; TGF-beta;
D O I
10.1016/j.jsbmb.2006.11.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vitamin D, especially its most active metabolite 1,25-dihydroxyvitamin D-3 or calcitriol, is essential in regulating a wide variety of biologic processes. such as calcium homeostasis, immune modulation, cell proliferation and differentiation. Clinical studies show that the circulating level of calcitriol is substantially reduced in patients with chronic renal insufficiency. Administration of active Vitamin D results in significant amelioration of renal dysfunction and fibrotic lesions in various experimental models of chronic kidney diseases. Active Vitamin D elicits its renal protective activity through multiple mechanisms, such as inhibiting renal inflammation, regulating renin-angiotensin system and blocking mesangial cell activation. Recent studies indicate that calcitriol induces anti-fibrotic hepatocyte growth factor expression, which in turn blocks the myofibroblastic activation and matrix production in interstitial fibroblasts. Furthermore, in vivo and in vitro studies demonstrate that active Vitamin D effectively blocks tubular epithelial to mesenchymal transition (EMT), a phenotypic conversion process that plays a central role in the evolution of renal interstitial fibrosis. Together, it is becoming increasingly clear that a high level of active Vitamin D may be obligatory in the maintenance of normal kidney structure and function. Thus, supplementation of active Vitamin D could be a rational strategy for the therapeutics of chronic kidney diseases. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:491 / 496
页数:6
相关论文
共 37 条
[11]   1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat [J].
Kuhlmann, A ;
Haas, CS ;
Gross, ML ;
Reulbach, U ;
Holzinger, M ;
Schwarz, U ;
Ritz, E ;
Amann, K .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2004, 286 (03) :F526-F533
[12]   Snail-regulated genes in malignant melanoma [J].
Kuphal, S ;
Palm, HG ;
Poser, I ;
Bosserhoff, AK .
MELANOMA RESEARCH, 2005, 15 (04) :305-313
[13]  
LEVIN A, 2005, J AM SOC NEPHROL, V16, pA35
[14]   Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure [J].
Li, YC ;
Qiao, GL ;
Uskokovic, M ;
Xiang, W ;
Zheng, W ;
Kong, J .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 89-90 (1-5) :387-392
[15]   Vitamin D regulation of the renin-angiotensin system [J].
Li, YC .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (02) :327-331
[16]  
Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI0215219, 10.1172/JCI200215219]
[17]   1,25-dihydroxyvitamin D3 inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression [J].
Li, YJ ;
Spataro, BC ;
Yang, JW ;
Dai, CS ;
Liu, YH .
KIDNEY INTERNATIONAL, 2005, 68 (04) :1500-1510
[18]   Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention [J].
Liu, YH .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (01) :1-12
[19]   Renal fibrosis: New insights into the pathogenesis and therapeutics [J].
Liu, YH .
KIDNEY INTERNATIONAL, 2006, 69 (02) :213-217
[20]   Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action [J].
Liu, YH .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2004, 287 (01) :F7-F16